Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of MP0310, a DARPin® therapeutic candidate for tumor
targeted activation of T cells, in patients with advanced solid tumors